IDBS and In Silico Discovery announces bioinformatics partnership
partnership in which the deal aims to integrate drug discovery data
and providing flexible access irrespective of where it is stored.
Current practices being developed in the bioinformatic field creates massive amounts of data. While the great strength of biological data adds to the depth of understanding, the worry is that the bottleneck that is forming will threaten to engulf all the good work that has been so far achieved.
"We are well used to handling the volume and complexity of data generated in modern drug discovery," said founder and CEO of IDBS, Neil Kipling.
"The challenge today's researchers face is that relevant data tends to be widely distributed in numerous private and public data silos and includes many different data types; chemistry, biology and image data. Getting access to this data is cumbersome and time consuming."
Under the terms of the agreement, IDBS' pharmaceutical data management tools including the new E-WorkBook (EWB) technology with ISD's data K3 integration platform.
This will allow researchers to use one compliant, portal to access data from multiple stores such as corporate silos, legacy databases and web-based repositories. No financial details of the deal were disclosed.
"K3 represents a technology developed by leading academics and with proven commercial applicability," said Brian Donnelly, CEO of ISD.
"Combining this with IDBS' applications and domain expertise we can now leverage this potential to address the problems being presented by Systems Biology and Translational Medicine."
Kipling added that the combination of EWB with K3 through this collaboration gives researchers the power to easily access ALL applicable information from one single point, and importantly as part of their day-to-day workflow.
